Normalization techniques for high-throughput screening by infrared matrix-assisted laser desorption electrospray ionization mass spectrometry.
IR-MALDESI
Orbitrap mass spectrometer
high-throughput screening
normalization
Journal
Journal of mass spectrometry : JMS
ISSN: 1096-9888
Titre abrégé: J Mass Spectrom
Pays: England
ID NLM: 9504818
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
21
05
2022
received:
02
05
2022
accepted:
26
05
2022
pubmed:
10
6
2022
medline:
11
6
2022
entrez:
9
6
2022
Statut:
ppublish
Résumé
Mass spectrometry (MS) is an effective analytical tool for high-throughput screening (HTS) in the drug discovery field. Infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) MS is a high-throughput platform that has achieved analysis times of sub-seconds-per-sample. Due to the high-throughput analysis speed, methods are needed to increase the analyte signal while decreasing the variability in IR-MALDESI-MS analyses to improve data quality and reduce false-positive hits. The Z-factor is used as a statistic of assay quality that can be improved by reducing the variation of target ion abundances or increasing signal. Herein we report optimal solvent compositions for increasing measured analyte abundances with direct analysis by IR-MALDESI-MS. We also evaluate normalization strategies, such as adding a normalization standard that is similar or dissimilar in structure to the model target drug, to reduce the variability of measured analyte abundances with direct analyses by IR-MALDESI-MS in both positive and negative ionization modes.
Identifiants
pubmed: 35678360
doi: 10.1002/jms.4869
pmc: PMC9287052
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e4869Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM087964
Pays : United States
Organisme : AbbVie
ID : None
Organisme : NIH HHS
ID : R01GM087964
Pays : United States
Informations de copyright
© 2022 The Authors. Journal of Mass Spectrometry published by John Wiley & Sons Ltd.
Références
Anal Bioanal Chem. 2019 Sep;411(22):5729-5743
pubmed: 31240357
SLAS Technol. 2019 Aug;24(4):386-393
pubmed: 30698995
Anal Chem. 2020 Feb 18;92(4):2931-2936
pubmed: 31967792
J Am Soc Mass Spectrom. 2020 Feb 5;31(2):319-325
pubmed: 32031399
Metabolites. 2021 Nov 18;11(11):
pubmed: 34822447
J Am Soc Mass Spectrom. 2018 Jan;29(1):8-16
pubmed: 28932998
Analyst. 2016 Sep 21;141(18):5236-45
pubmed: 27484166
J Biomol Screen. 2016 Feb;21(2):176-86
pubmed: 26428484
Science. 1989 Oct 6;246(4926):64-71
pubmed: 2675315
Anal Chem. 2007 Nov 1;79(21):8207-13
pubmed: 17902631
J Biomol Screen. 2006 Apr;11(3):247-52
pubmed: 16490779
Br J Pharmacol. 2011 Mar;162(6):1239-49
pubmed: 21091654
Anal Chem. 2022 Mar 15;94(10):4141-4145
pubmed: 35234449
Science. 2004 Oct 15;306(5695):471-3
pubmed: 15486296
J Proteomics. 2012 Aug 30;75(16):5111-5112
pubmed: 22641155
Chem Sci. 2018 Jan 4;9(6):1647-1653
pubmed: 29675211
J Am Soc Mass Spectrom. 2006 Dec;17(12):1712-6
pubmed: 16952462
J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
Anal Chem. 2021 May 4;93(17):6792-6800
pubmed: 33885291
Mass Spectrom Rev. 2021 May 24;:
pubmed: 34028071
Anal Bioanal Chem. 2011 Jul;401(1):167-81
pubmed: 21479971
ACS Med Chem Lett. 2020 Sep 21;11(11):2108-2113
pubmed: 33214819
Nat Biotechnol. 2012 Oct;30(10):918-20
pubmed: 23051804
Rapid Commun Mass Spectrom. 2017 Nov 30;31(22):1868-1874
pubmed: 28841760
J Mass Spectrom. 2022 Jun;57(6):e4869
pubmed: 35678360
Anal Chem. 2019 Mar 19;91(6):3790-3794
pubmed: 30835099
J Am Soc Mass Spectrom. 2022 Feb 2;33(2):328-334
pubmed: 35073091
Anal Chem. 2005 Apr 15;77(8):2297-302
pubmed: 15828760
Methods Mol Biol. 2016;1439:47-63
pubmed: 27316987
Anal Chem. 2012 Feb 7;84(3):1310-9
pubmed: 22148759
Anal Chem. 2021 Aug 10;93(31):10850-10861
pubmed: 34320311
J Am Soc Mass Spectrom. 2013 May;24(5):718-21
pubmed: 23536269
J Am Soc Mass Spectrom. 2020 Dec 2;31(12):2547-2552
pubmed: 32539373